ErbBs in Lens Cell Fibrosis and Secondary Cataract
Authors:
Open Access
- 7 July 2023
- journal article
- research article
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 64 (10) , 6
Abstract
Purpose: TGFβ-induced epithelial-to-myofibroblast transition (EMyT) of lens cells has been linked to the most common vision-disrupting complication of cataract surgery—namely, posterior capsule opacification (PCO; secondary cataract). Although inhibitors of the ErbB family of receptor tyrosine kinases have been shown to block some PCO-associated processes in model systems, our knowledge of ErbB signaling in the lens is very limited. Here, we investigate the expression of ErbBs and their ligands in primary cultures of chick lens epithelial cells (dissociated cell-derived monolayer cultures [DCDMLs]) and how TGFβ affects ErbB function. Methods: DCDMLs were analyzed by immunofluorescence microscopy and Western blotting under basal and profibrotic conditions. Results: Small-molecule ErbB kinase blockers, including the human therapeutic lapatinib, selectively inhibit TGFβ-induced EMyT of DCDMLs. Lens cells constitutively express ErbB1 (EGFR), ErbB2, and ErbB4 protein on the plasma membrane and release into the medium ErbB-activating ligand. Culturing DCDMLs with TGFβ increases soluble bioactive ErbB ligand and markedly alters ErbBs, reducing total and cell surface ErbB2 and ErbB4 while increasing ErbB1 expression and homodimer formation. Similar, TGFβ-dependent changes in relative ErbB expression are induced when lens cells are exposed to the profibrotic substrate fibronectin. A single, 1-hour treatment with lapatinib inhibits EMyT in DCDMLs assessed 6 days later. Short-term exposure to lower doses of lapatinib is also capable of eliciting a durable response when combined with suboptimal levels of a mechanistically distinct multikinase inhibitor. Conclusions: Our findings support ErbB1 as a therapeutic target for fibrotic PCO, which could be leveraged to pharmaceutically preserve the vision of millions of patients with cataracts.Keywords
This publication has 126 references indexed in Scilit:
- Actin cytoskeleton in myofibroblast differentiation: Ultrastructure defining form and driving functionTranslational Research, 2011
- Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036Cancer Cell, 2011
- Regulation of Lens Gap Junctions by Transforming Growth Factor BetaMolecular Biology of the Cell, 2010
- Functional selectivity of EGF family peptide growth factors: Implications for cancerPharmacology & Therapeutics, 2009
- The lens capsuleExperimental Eye Research, 2009
- Upregulation and maintenance of gap junctional communication in lens cellsExperimental Eye Research, 2008
- Structural basis for inhibition of the epidermal growth factor receptor by cetuximabCancer Cell, 2005
- The ErbB signaling network: receptor heterodimerization in development and cancerThe EMBO Journal, 2000
- Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimersThe EMBO Journal, 1998
- ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingThe EMBO Journal, 1997